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A 28-year-old white man, first demonstrated to be human immunode-
ficiency virus (HIV) positive 2.5 years ago, presented 6 months later with
an expanding scalp mass. Biopsy of this lesion, which was shown by CT
scan to extend into the dura, revealed high-grade non-Hodgkin's lym-
phoma. Radiochemotherapy for the lesion, consisting of 300 cGy, plus
adriamycin, bleomycin, vincristine, and dexamethasone, produced a good
response. Over the next 6 months, the patient had two episodes of
Pneumocystis carinii pneumonia, which responded first to trimethoprim!
sulfamethoxazole and then to pentamidine therapy. In addition, an
intrahepatic mass noted on an abdominal CT scan was consistent with
recurrent lymphoma. Because of these problems, he was referred to the
Fred Hutchinson Cancer Research Center for treatment with an experi-
mental protocol comprising lethal doses of radiochemotherapy designed
to eradicate both the malignancy and the lymphohematopoietic system,
the principal reservoir of HIV; the cytoreductive therapy is followed by
bone marrow transplantation. Following marrow infusion, zidovudine
(AZT) and cloned CD8+ lymphocytes, obtained from the patient pre-
transplantation, are administered to combat residual HIV. The CD8+
cells, selected for their reactivity to the HIV gag protein, are expanded in
vitro and transduced with a retrovirus, thereby introducing a thymidine
kinase "suicide gene." This gene confers susceptibility to ganciclovir, so
that these cells can be ablated in vivo should severe immunologic
complications develop.
The patient received 120 mg/kg cyclophosphamide and 1200 cGy
total-body irradiation prior to marrow transplantation, which was accom-
plished using an HLA-identical graft from his brother. The cloned T-cells
(CD8 +) were infused subsequently. Within one week after cytoreductive
therapy, marrow aplasia developed, which was complicated by corynebac-
terium bacteremia manifested by severe rigors and profound hyperther-
mia (up to 41.3°C). Myoglobinuria resulted, which, in concert with
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tobramycin therapy, induced oliguric acute renal failure. A diagnosis of
acute tubular necrosis was made. Cyclosporine, administered for graft-
versus-host disease prophylaxis, was stopped. The patient regained renal
function after 3 days of hemodialysis. His hospital course was further
complicated by hepatic insufficiency, progressive jaundice, and mild
azotemia, however. During his fourth week of hospitalization, his renal
function again rapidly deteriorated. A microangiopathic hemolytic ane-
mia, worsening thrombocytopenia, proteinuria, and red blood cell casts in
the urine sediment were noted, and a diagnosis of hemolytic-uremic
syndrome (HUS) was made. The patient underwent 14 plasma exchanges,
but without hematologic or renal functional improvement, and he re-
quired alternate-day hemodialysis. Despite adequate marrow engraft-
ment, multiple infectious complications ensued; these included bacterial
and cytomegalovirus pneumonitis as well as central nervous system
aspergillosis. The patient succumbed to these infections after 2 months of
hospitalization. Renal tissue obtained at autopsy revealed multiple arte-
riolar and glomerular capillary thrombi, consistent with the clinical
diagnosis of HUS.
Discussion
DR. RIctiAjw A. ZAGER (Professor of Medicine, Fred Hutchinson
Cancer Research Center, Seattle, Washington): Worldwide, approx-
imately 5000 bone marrow transplants (BMT) are conducted
annually, and the list of indications continues to grow. Currently,
indications include aplastic anemia, hematologic and non-hema-
tologic malignancies, hereditary enzyme deficiencies, immunode-
ficiency states, and selected hemoglobinopathies. As illustrated by
the patient presented here, the therapeutic utility of BMT con-
tinues to be tested. Aggressive investigation of the utility of BMT
should provide us with new insights into disease mechanisms and
treatment-related toxicities.
One of the most frequent and potentially life-threatening
complications of marrow transplantation is acute renal failure
(ARF). Approximately 40% of patients develop renal insufficiency
early in the course of this treatment, and approximately 50% of
these individuals require dialysis (Fig. 1). This high incidence of
ARF is by no means unexpected, given the life-threatening nature
of the underlying diseases and the toxicities inherent to the
cytoreductive-radiochemotherapeutic preparatory regimens. In-
deed, the patient presented here developed three distinct ARF
syndromes during his 2-month hospitalization. First, sepsis, pro-
found hyperthermia, myoglobinuria, and tobramycin therapy re-
sulted in acute tubular necrosis. Next, hepatic insufficiency led to
mild renal insufficiency, probably on a hemodynamic basis. Fi-
nally, the patient developed classic manifestations of HUS. Thus,
this case graphically depicts the varied forms of ARF that
frequently befall this patient population.
The purpose of this review is to present an overview of several
renal syndromes that are either unique to, or occur with a
disproportionate frequency in, BMT patients. These syndromes
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Fig. 1. Time distribution and frequency of renal
syndromes in the setting of bone marrow
transplantation. The solid line depicts the
approximate frequency of renal insufficiency, as
defined by at least a doubling of the baseline
serum creatinine concentration (azotemia); the
dotted line represents the frequency of dialysis-
requiring ARF [32]. During the period of
conditioning, tumor lysis syndrome and stored
marrow-infusion toxicity are most common;
between 10—28 days, the peak incidence of
ARF is observed, most notably due to a veno-
occlusive-disease-associated hepatorenal-like
syndrome. Beyond one month, the hemolytic-
uremic syndrome, and less commonly chronic
cyclosporine toxicity, can be observed. (The
frequency with which these require dialytic
support is not known.) HUS, hemolytic-uremic
syndrome; CSA, cyclosporine A.
can best be subdivided clinically according to characteristic times
of onset, and I will present them in that order. First, immediate
ARF syndromes (within the first 5 days) will be discussed, most
notably the tumor lysis syndrome and stored marrow-infusion-
associated toxicity. Next, we will look at a hepatorenal-like
syndrome that generally occurs within the first month post
transplantation. Finally, I will present the relatively late (after 4
weeks) post-BMT-associated renal disorders, notably the hemo-
lytic-uremic syndrome and chronic cyclosporine nephrotoxicity.
Immediate renal syndromes
Tumor lysis syndrome. The tumor-lysis syndrome (TLS) is a
potential life-threatening complication of cytoreductive therapy in
patients with rapidly growing and hence highly radiochemo-
therapy-sensitive tumors [reviewed in Ref. 1, 2]. This syndrome is
of particular concern in individuals who have extensive, rapidly
growing, and radiochemosensitive tumors, because the release of
tumor-derived intracellular constituents into the systemic circula-
tion, with their subsequent filtration into tubular luinina, is
believed responsible for the resulting ARF. The best-documented
tumor-derived products thought to play pathogenetic roles in the
renal injury are uric acid, phosphate, and xanthine [11. Xanthine
accumulates when xanthine oxidase inhibitors (such as allopuri-
nol) are given to prevent urate production as a result of purine
breakdown. Since uric acid, xanthine, and phosphate have low
urinary solubilities, intratubular precipitation can result, causing
intratubular obstruction and hence ARF [1].
Although lethal doses of radiochemotherapy are given to BMT
patients in an attempt to eradicate malignancy, the incidence of
TLS in this patient population is surprisingly low, with only a few
cases reported [3, 41. Atour institution, approximately one in 400
patients develops overt TLS and attendant renal failure. The
reasons for this low incidence are unclear, but two possible
explanations exist. (1) The majority of patients undergoing BMT
have disease in relapse, not de-novo disease, and hence their
tumor burden usually is not extreme. (2) Given the widespread
recognition of this syndrome, patients routinely receive prophy-
laxis with vigorous volume expansion/hydration, urinary alkalin-
ization, and allopurinol therapy. If extreme leukocytosis exists
prior to radiochemotherapy, leukapheresis can be used. Finally, if
TLS does develop, early hemodialysis is initiated to remove
circulating purine by-products and phosphate in an attempt to
limit renal toxicity.
Marrow infusion toxicity. Bone marrow transplantation has
increasingly employed autologous marrow for reconstituting the
hematopoietic system following cytoreductive therapy, thereby
avoiding the need for marrow donors, related or unrelated [5].
However, cryopreservation of the harvested marrow is usually
required, since hematopoietic stem cells generally die within a few
days of storage at 4°C [6]. Cryopreservation is generally per-
formed at —80°C, with 10% dimethyl sulfoxide (DMSO) added as
a cytoprotectant. Although progenitor cells are well maintained
during freezing, storage, and thawing, granulocytes and red blood
cells are disrupted [7]. Thus, during marrow infusion, patients are
exposed to potentially toxic cell lysis products, as well as to
DMSO. Reported side effects include nausea, vomiting, abdomi-
nal pain, dyspnea, headache, flushing, fever, chills, hyper- and
hypotension, as well as bradycardia with 1st, 2nd, or 3rd degree
heart block [6—9]. In addition, overt hemoglobinuria occurs in
approximately 75% to 100% of such patients [8, 10, 11]. The free
hemoglobin load results from cryopreservation-induced red blood
cell disruption, as well as from in-vivo hemolysis. The latter is a
frequent complication of DMSO infusion, particularly when high
concentrations (>10%) or large total amounts are employed [10,
12, 13]. In-vivo hemolysis also can occur with peripheral stem cell
grafts, as their collection via apheresis produces a dilute stem cell
population and necessitates large-volume DMSO infusions [10].
In 1987, Smith et al noted the potential for marrow infusion to
cause ARF [11]. These investigators reviewed 33 consecutive
cases of autologous BMT and identified 3 patients who developed
ARF immediately after administration of cryopreserved marrow.
They concluded that the ARF was hemoglobin induced because
the onset of the ARF was not associated with hypotension or
nephrotoxic drug exposure, gross hemoglobinuria occurred in all
33 patients, and the renal histology showed dilated tubules with
hemoglobin casts and acute tubular necrosis. I should note that
DMSO-induced intravascular hemolysis can cause ARF even in
the absence of BMT [12], so marrow products are not essential for
the induction of this syndrome.
1444 Nephrology Fomm: ARFand bone marrow transplantation
C
a
0
60
50
40
30
20
10
0
—10
Conditioning
0 7 14 21 28 lyr
Time, days
Nephrology Forum: ARF and bone marrow transplantation 1445
The mechanisms by which heme proteins (hemoglobin/myoglo-
bin) induce ARF have been extensively studied for many years,
but as of yet, no single, unifying hypothesis has emerged. How-
ever, at least three interrelated pathophysiologic alterations prob-
ably are involved (reviewed in Ref. 13). First, following their
filtration, heme proteins precipitate within distal nephron seg-
ments, particularly in the presence of an acid pH (<6.5). Because
heme proteins and Tamm-Horsfall protein each precipitate and
co-aggregate under aciduric conditions [14, 15], cast formation
with early tubular obstruction results. That cast formation is a
critical event in the evolution of heme-protein-induced ARF is
underscored by innumerable studies documenting that prevention
of heme precipitation, either by urinary alkalinization or by
administration of impermeant solute (for example, mannitol,
Na2SO4), can protect against subsequent ARF [13—18].
Second, proximal tubular heme protein uptake occurs via
endocytic reabsorption and leads to cellular heme overload. The
presence of heme protein casts undoubtedly increases this process
because tubular obstruction prevents heme protein excretion,
allowing more time for proximal tubular endocytic reabsorption to
occur. To demonstrate this point, our laboratory compared the
amount of proximal tubular heme protein endocytic uptake by
normal rats and by rats subjected to extrarenal (ureteral) obstruc-
tion [14]. Whereas relatively mild endocytic heme uptake oc-
curred in normal rat kidneys, rats with ureteral obstruction
developed rapid and massive proximal tubular heme protein
overload, as denoted by giant heme-stained endolysosome forma-
tion [14]. Thus, the amount of proximal tubular heme uptake, a
critical determinant of subsequent heme protein cytotoxicity, does
not merely depend on the magnitude of hemoglobinuria, but also
on the presence of obstructing casts.
Third, proximal tubular heme loading eventuates in tubular cell
necrosis. However, the mechanisms involved remain ill defined.
Of note, neither hemoglobin nor myoglobin is acutely toxic to
either cultured proximal tubular cells [19] or to freshly isolated
proximal tubular segments [20]. Indeed, these proteins paradoxi-
cally can exert cytoprotective influences [20, 21], possibly because
of their ability to scavenge nitric oxide, which is produced within
proximal tubular cells [21]. It is generally believed that heme
proteins, once they have gained an intracellular location, must be
metabolically "processed," and that this process culminates in the
generation of toxic by-products. The most commonly discussed is
inorganic iron, released from the porphyrin ring. Once freed, it
can catalyze the formation of highly toxic hydroxyl radical (OH)
via the Fenton/Haber Weiss reactions and can initiate a chain of
oxidative reactions that culminate in cell death. In support of this
theory are several reports that deferoxamine, an iron chelator, can
mitigate in-vivo myohemoglobinuric ARF [22—24]. But deferox-
amine can prevent iron-induced tubular cell killing in vitro despite
paradoxically increasing OH generation [20, 24]. Furthermore,
free-radical-induced lipid peroxidation can exert cytoprotective,
as well as injurious, proximal tubular effects [25]. Therefore, the
mechanisms by which heme proteins induce tubular cell necrosis
remain speculative. Study of this issue is further complicated by
the fact that non-iron-containing, low-molecular-weight proteins
also can cause renal injury; heme protein nephrotoxicity thus is
not simply a result of iron-dependent oxidant stress [26, 27].
Despite the frequency of hemoglobinuria during ciyopreserved
marrow infusion, ARF uncommonly results, undoubtedly because
a prophylactic solute and bicarbonate diuresis is routinely induced
[7]. This diuresis prevents cast formation and hence the initiating
step in heme protein nephrotoxicity. Of further note is that
DMSO, contained within the marrow infusate, might exert a
cytoprotective influence by contributing to the solute diuresis, and
possibly by functioning as a free-radical scavenger. Indeed,
DMSO's potential for protecting against acute tubular necrosis
(ATN) is underscored by a study in which its administration
mitigated post-ischemic renal injury in rats [28]. However, this
protective influence is by no means universal; Bennett et al
showed that it had no effect on potassium-dichromate-induced
ARF [29].
An unresolved issue is whether marrow-infusion-induced prox-
imal tubular cell heme protein loading alters the kidney's suscep-
tibility to ischemic or toxic insults sustained later in the post-
transplant period. In this regard, Nath and colleagues have
demonstrated that administration of nontoxic amounts of heme
proteins increase heme oxygenase and ferritin concentrations
within renal cortex [30]. These proteins function as antioxidants,
so theoretically they could protect the kidney from subsequent
tubular insults [30]. Alternatively, our laboratory has found that
heme infusions raise intratubular cell free-iron content, sensitiz-
ing these cells to superimposed oxidant (H202) stress [31]. Thus,
the long-term effect of renal heme/iron loading on post-BMT
renal function remains an interesting, but unresolved, issue.
Early hepatorenal-like syndrome
By far the most common time frame in which BMT-associated
ARF develops is within the first 10 to 21 days post transplantation.
It is during this period that most of the acute complications of
radiochemotherapy become manifest, including marrow aplasia,
life-threatening infections, pneumonitis, and gastrointestinal and
hepatic toxicities. At our institution, approximately 40% of pa-
tients develop renal insufficiency during this period (as defined by
a doubling at least of the baseline serum creatinine concentra-
tion), and one-half of these individuals require dialysis (Fig. 1)
[32]. Our experience is not unique. For example, Johns Hopkins
University School of Medicine reported a 64% incidence of early
BMT-associated renal insufficiency [33], and a recent study from
Madrid, Spain, noted an 84% occurrence rate [34]. The develop-
ment of ARF during this period has profound implications for
patient survival. For example, a doubling of the serum creatinine
is associated with a twofold increase in mortality (from 17% to
37%) [32], whereas the need for dialysis predicts a mortality rate
of 84% to 88% [32, 34]. Thus, it is clear that early BMT-associated
renal dysfunction has ominous implications.
To discern the types of ARF that develop during this early
period after BMT, we conducted an extensive retrospective review
of 272 patients who received bone marrow transplants in 1986 at
our institution [32]. A priori we assumed that patients who
developed ARF during the early post-transplant period would
manifest a broad spectrum of renal diseases, not a specific
syndrome, because of the multiple and diverse risk factors for
renal dysfunction that exist in these critically ill patients. As
examples, nausea, vomiting, and diarrhea due to radiochemo-
therapy and to acute graft-versus-host disease (GVHD) can cause
intravascular volume depletion, and hence, a pre-renal state.
Frequent nephrotoxic drug exposure (such as with aminoglyco-
sides, amphotericin B) and hemorrhagic and septic shock would
seem likely causes of ATN. These patients are exposed to a wide
variety of drugs, such as semisynthetic penicillins, cephalosporins,
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and allopurinol, which have the potential for inducing allergic
interstitial nephritis. As I will discuss in a moment, BMT is a
frequent cause of the hemolytic-uremic syndrome (HUS). Finally,
high-dose methotrexate [35], hemorrhagic cystitis with clot forma-
tion, and fungal involvement of the collecting system each can
cause obstructive nephropathy. Thus, a wide range of possibilities
exists, and a complete differential diagnostic evaluation is needed
in these patients.
Despite this broad range of diagnostic possibilities, our experi-
ence indicates that approximately 90% of patients who develop
early BMT-associated ARF manifest a single disorder that mimics
the hepatorenal syndrome (HRS) [32]. Its clinical characteristics
are as follows. Within one to 7 days after marrow infusion, a
sodium-retentive state develops that leads to weight gain (approx-
imately 2—6 kg within 2 weeks), peripheral edema, and sometimes
ascites. Concomitant hepatic dysfunction due to veno-occiusive
disease almost always occurs and is manifested by progressive
hyperbilirubinemia. The onset of azotemia characteristically be-
gins between 10 and 16 days post transplantation and, within an
additional 5 to 7 days, approximately one-half of the affected
individuals require dialysis for control of ARF. More than 80% of
these patients have a persistently low urinary sodium concentra-
tion (<20—40 mEq/liter) despite the use of diuretics. Urinalysis
typically demonstrates only trace protein but the urine sediment
often contains large numbers of "muddy brown" granular casts.
These casts are also present in comparably jaundiced BMT
patients who do not have ARF; thus the casts are likely a
consequence of bile salt/bilirubin effects on tubules [36], rather
than indicators of A1'N. Approximately two-thirds of the patients
are nonoliguric; however, substantial fluid requirements for med-
ications and nutritional support plus refractoriness to diuretics
often lead to progressive volume expansion and pulmonary vas-
cular congestion. Indeed, volume overload with pulmonary vas-
cular congestion, not severe azotemia, is the usual indication for
initiating dialysis [32]. The mean BUN and creatinine concentra-
tions at this time are approximately 100 mg/dl and 3.5 mg/dl,
respectively [32]. After dialysis is begun, oliguria frequently
supervenes.
The central role for hepatic disease in this form of ARF is
underscored by the facts that jaundice, portal hypertension, and
renal sodium avidity precede the onset of azotemia, and that the
severity of these abnormalities predicts the likelihood that the
patient will require dialysis [32,34]. For example, a biirubin of <4
mgldl portends a relatively good renal prognosis; conversely, a
bilirubin of >7 mg/dl at the time of serum creatinine doubling
predicts a high likelihood for the subsequent need for hemodial-
ysis. Multiple potential causes for hepatic disease exist in this
patient population. These include drug-induced and viral hepati-
tis, hyperalimentation-induced fatty liver, and acute graft-versus-
host disease. By far the most common cause, accounting for 90%
of cases, is veno-occlusive disease [37—41] (Fig. 2). Veno-occlusive
disease is caused by acute radiochemotherapy-induced endothe-
hal cell injury of hepatic venules, with its resultant venular
thrombosis, possible collagen and reticulum fiber deposition, and
ultimately sinusoidal and portal hypertension. In addition, vari-
able degrees of zone-three hepatocyte necrosis occur, and the
serum transaminases rise modestly. Jaundice results from intra-
hepatic portal vein-systemic venous shunting and hepatocyte
necrosis. With the onset of ARF, the degree of hyperbiliru-
binemia is exacerbated because bilirubin is not excreted, and
serum concentrations of greater than 50 mg/dl are frequently
observed.
A number of pre-transpiant risk factors for veno-occiusive
disease can predict which individuals are at risk of developing the
associated ARF. These include pre-existing hepatic disease, fever
during cytoreductive therapy, and selected medications (estrogen-
progestin, amphotericin, methotrexate) [38, 42]. Additional risk
factors for ARF include mismatched grafts, age greater than 25
years, and a mildly elevated baseline serum creatinine concentra-
tion [32]. The vast majority of patients undergoing BMT have
normal pre-transplant serum creatinine levels. Small differences
within the normal range seem to predict different renal outcomes,
however. For example, mean pre-transplant serum creatinine
levels (measured after vigorous volume expansion) for groups that
subsequently do or do not develop ARF are 0.75 0,02 and 0.65
0.02 mg/dl, respectively (P < 0.001) [32]. Thus, even a slight
reduction in renal functional reserve appears to predict an
increased risk of early BMT-associated acute renal failure [32].
The clinical similarities between this syndrome and hepatorenal
syndrome are striking. (1) Jaundice and portal hypertension
precede the onset of ARF. (2) Sodium avidity is almost always
present, even when severe azotemia exists. (3) The BUN/creati-
nine ratio is typically high (—'30/1), again suggesting a hemody-
namic form of ARF. (4) Mild hyponatremia, a common feature of
hepatorenal syndrome, is frequently observed [43]. (5) Systemic
arterial blood pressure is usually low (—90—100 mm Hg systolic),
suggesting peripheral vasodilation, as in hepatorenal syndrome
[43]. (6) Autopsy material obtained from 36 patients dying with
this syndrome at our institution failed to reveal any structural or
morphologic basis for the ARF [32]. Although postmortem autol-
ysis precluded definitive exclusion of ATN, when these negative
morphologic results are interpreted in light of the pertinent
clinical and laboratory parameters, a hemodynamic, rather than
structural, form of ARF appears highly likely.
Although veno-occlusive disease sets the stage for most cases of
early BMT-associated ARF, a superimposed clinical event usually
triggers the development of renal failure (Fig. 3). The most
common, in our experience, is sepsis syndrome. For example, in
our retrospective analysis, fever and positive blood cultures were
observed in 95% and 63% of patients, respectively, within the 48
hours prior to the onset of renal insufficiency [32]. Conversely, the
incidence of hypotension did not increase during this period.
Since more than 50% of the positive blood cultures contain
fungus, amphotericin B therapy is generally initiated at this time;
indeed, its use is the single strongest clinical association with the
onset of ARF. Whether amphotericin B is directly involved in
triggering ARF (for example, due to its vasoconstrictive proper-
ties) [44], or whether it is merely a marker for sepsis, which then
precipitates the renal failure, remains unknown. However, that
amphotericin B is typically administered for only one to 3 days,
not weeks, prior to the development of azotemia strongly suggests
that its adverse influence is not due to direct tubulotoxicity, which
requires more prolonged administration to develop [45]. In our
experience, neither aminoglycosides nor cyclosporine (CSA)
exposure significantly increases the frequency of acute renal
failure soon after BMT [32, additional unpublished data]. This is
surprising because liver disease is a major risk factor for amin-
oglycoside toxicity [46, 47], and because CSA would be expected
to exacerbate a hemodynamic form of ARF given its vasocon-
strictor effects. Thus, while these drugs might contribute to ARF in
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Fig. 2. A Gross appearance of a liver with severe
veno-occlusive disease. Marked vascular
congestion, swelling, and bile staining are
apparent. B Histologic reticulum-stained section
of liver showing a hepatic venule and its tributaiy,
which are laiely occluded with a network of
reticulum fibers.
selected patients, these compounds are not simple explanations
for the vast majority of cases at our institution.
Because this form of ARF resembles hepatorenal syndrome
clinically, it probably is hemodynamic in origin, being mediated by
a primary increase in renal vascular resistance. That sequential
isotopic blood flow measurements, conducted on 4 patients, have
documented approximate 50% decrements in renal perfusion with
the onset of renal insufficiency further supports this view (person-
al unpublished data). The mediators of this vasoconstriction
remain unknown. By analogy with hepatorenal syndrome, multi-
ple possibilities exist, including endotoxemia, false neurotransmit-
ters, excess catechol production, increased renal sympathetic
tone, altered prostaglandin synthesis, excess angiotensin II gener-
ation, and defects in the kallikrein-kinin system [reviewed in 43].
Endothelin recently was implicated in hepatorenal syndrome
because circulating levels were preferentially increased in cir-
rhotic patients who developed this form of renal failure [481.With
these diverse pathogenetic possibilities, and given that sepsis [49],
amphotericin B [44], and cyclosporine each can induce renal
vasoconstriction, it will be extremely difficult to identi' the
specific mediators of this syndrome in BMT patients.
Veno-occiusive disease, sepsis, and amphotericin B are the
principal risk factors for early BMT-associated acute renal failure,
and a number of prophylactic and therapeutic approaches have
been developed to combat each. Various modifications of cytore-
ductive therapy have been tried in an attempt to minimize the
hepatic injury that gives rise to veno-occlusive disease [37].
Continuous heparin [50—53] and PGE1 infusions [54, 55] also
have been used to prevent hepatic venular thrombosis and, hence,
portal hypertension. Unfortunately, these approaches have met
with inconsistent success. In an attempt to reverse severe veno-
occlusive disease, Bearman and colleagues at this institition
conducted a trial of tissue plasminogen activator (tPA) plus
heparin therapy [56]. This combined therapy reduced jaundice
and increased urine output in 5 of 7 patients. But the high risk of
hemorrhage in these patients limits broad application of this
approach. Because protein C and anti-thrombin-Ill deficiencies
might be involved in the pathogenesis of veno-occiusive disease
[57], therapeutic trials with these naturally occurring anticoagu-
lants are planned.
A number of approaches for preventing sepsis and its compli-
cations also have been undertaken. For example, treatment with
granulocyte-macrophage colony stimulating factor (GM-CSF)
might accelerate recovery from neutropenia, potentially decreas-
ing infectious complications, and possibly reducing the incidence
of ARF. Because regimen-related toxicities are associated with
TNFa generation [37], and since the latter is responsible for many
components of sepsis [49], research has centered on blocking its
production with pentoxif'lline (PTX). When PTX was given to 30
BMT recipients in a phase I-I! trial, lessening of the early
BMT-associated hepatic and renal dysfunction appeared to result
[58]. However, a more recent randomized trial of PTX has shown
no beneficial effects of the drug [59].
Approaches taken to eliminate the risk of amphotericin B
nephrotoxicity include combined fluconazole and low-dose am-
photericin B prophylaxis [60, 61]. It is hoped that preventing
fungal sepsis will obviate the need for full therapeutic, and hence
nephrotoxic, amphotericin B doses. However, the utility of this
approach remains to be determined. Alternatively, new ampho-
tericin B formulations might decrease its toxicity. One such
compound (ABCD; Liposomes Technology, Inc., Menlo Park,
California) is currently undergoing clinical trials at our institution.
In this formulation, amphotericin is complexed with cholesteiyl
sulfate; its ability to insert into mammalian cell membranes is
decreased and its toxicity thereby reduced [62, 63]. A recent
in-vitro study from our laboratory illustrates this point [64].
Freshly isolated rat proximal tubular segments were incubated
with either traditional amphotericin B (Fungizone) with sodium
deoxycholate (the bile salt dispersing agent used in the Fungizone
preparation) or with ABCD. Under the conditions employed,
Fungizone caused approximately 40% cell death and about 90%
cellular ATP depletion during 60 minutes of incubation. Approx-
imately one-half of this toxicity could be directly attributed to the
deoxycholate carrier, undoubtedly because of its detergent effect.
In contrast, ABCD caused absolutely no cytotoxicity, even when
the concentrations were increased threefold above the Fungizone
levels. The ABCD was completely nontoxic when the proximal
tubules were subjected to superimposed hypoxic injury. Experi-
mental in-vivo studies also suggest an absence of nephrotoxicity
[62,63]. Nevertheless, the utility and safety of this promising agent
in the clinical setting remain to be defined.
Once ARF develops, management is supportive. Attempts at
maintaining normal fluid balance with sodium and water restric-
tion and loop diuretics generally have met with little success.
Low-dose dopamine infusion has been largely abandoned at our
institution because of poor therapeutic responses. Dialysis thus
remains the mainstay of treatment.
Late renal syndromes
Hemolytic-uremic syndrome. In 1981, Shulman et al reported 3
patients who developed arterial hypertension, microangiopathic
hemolytic anemia, and severe renal failure within 6 weeks after
bone marrow transplantation [65]. Histologic evaluation of renal
tissue samples obtained at autopsy revealed similar findings in
each of the 3 patients. The most prominent changes were afferent
arteriolar and glomerular capillary thrombi, tubular dilation with
intraluminal debris, red blood cell/hemoglobin casts, and focal
tubular necrosis. The microangiopathy and the characteristic
clinical presentation led these researchers to conclude that these
individuals had developed hemolytic-uremic syndrome. That each
of these patients had received cyclosporine, that CSA had previ-
ously been reported to cause vascular injury, and that microangi-
opathy had not been observed in non-CSA-treated BMT patients
led the authors to hypothesize that this syndrome was CSA-
induced.
Since Shulman's report, BMT-associated HUS has been widely
recognized, with more than 20 reports appearing in the literature
[66—85]. Its most characteristic presentation is an acute nephritic
syndrome, with moderate to severe hypertension, hematuria/red
blood cell casts, proteinuria, and renal failure (usually noted 4 to
12 months post BMT). In addition, central nervous system
abnormalities (that is, perturbations triggered by hypertensive
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Fig. 3. Schematic representation of the major
pre-existing risk factors and acute precipitating
factors for veno-occiusive-disease-associated ARF.
These factors are believed to predispose to, or
cause, renal vasoconstriction, which culminates
in decreasing renal blood flow (RBF) and
hence lowered glomerular filtration rate (GFR).
•
r 
z.
 '!b
'c 
A!
: Nephrology Forum: ARE and bone marrow transplantation 1449
Fig. 4. Characteristic glomerular pathology in renal biopsy samples obtained from a patient with BMT-associated HUS. A An afferent arteriolar intraluminal
thrombus and collapse of glomerular capillary tufts are observed (silver methenamine stain). B Widespread glomerular capillary thrombi are depicted,
which appear to contain fragmented red blood cells and hemoglobin (Mason trichrome). C Mesangial dissolution ("mesangiolysis"), splitting of
glomerular basement membranes, and intraluminal clots are present (silver methenamine stain).
encephalopathy, intracranial hemorrhage, and/or thrombotic mi-
croangiopathy) have been commonly observed, often dominating
the disease. The nephritic presentation and the frequency of
infection in this patient population sometimes lead to a presump-
tive diagnosis of postinfectious glomerulonephritis. However,
microangiopathic hemolytic anemia and its consequences (schis-
tocytes, depressed haptoglobin, elevated lactic dehydrogenase
concentrations) plus the onset, or worsening, of thrombocytope-
nia typically clarify the diagnosis. Thus, a renal biopsy usually is
not required.
Over the past 10 years, retrospective and prospective studies
have ascertained the frequency and potential causes of BMT-
associated hemolytic-uremic syndrome. An overall incidence of
approximately 15% to 20% has been found; one study reported a
71% occurrence rate [71]. Documented in all age groups, its
incidence appears unrelated to the disease for which transplanta-
tion is performed, and it has been observed following both
allogeneic and autologous grafting. Other than exposure to cy-
toreductive therapy, no consistent preexisting or precipitating
conditions have been identified. Enough cases of BMT-associated
HUS have been documented in the absence of cyclosporine
treatment [72, 75, 80] to indicate that the drug either is not
responsible for the syndrome or is not a prerequisite for its
development. These retrospective and prospective analyses also
have more completely defined the clinical spectrum of this
disease. Whereas early reports stressed a fulminant nephritic
presentation, it has become clear that more subtle cases are at
least as frequent. For example, the syndrome can manifest as
subacute or insidious renal failure; furthermore, microangiopathic
hemolytic anemia and thrombocytopenia may be minimal or not
immediately apparent. Under these circumstances, a diagnosis of
chronic cyclosporine nephrotoxicity may be entertained. Alterna-
tively, HUS may remain entirely subclinical, its presence only
being documented by careful laboratory assessments for microan-
giopathic hemolytic anemia, by transient thrombocytopenia, or by
subtle abnormalities on urinalysis.
The clinical course of BMT-associated HUS is quite variable.
Because the early literature stressed fulminant cases, death or
irreversible renal failure has been reported most frequently.
However, as the spectrum of the disease has become more
apparent, it is clear that this disease also can run a self-limited
course with resolution of the microangiopathic hemolytic anemia
and thrombocytopenia. Most series have noted that renal insuffi-
ciency or renal failure, once it develops, usually remains fixed and
frequently necessitates chronic dialysis. Some cases of reversible
acute renal failure also have been noted, however. As Shulman et
al pointed out [65], acute tubular necrosis can complicate this
disease, and its resolution may explain many of these reversible
cases. Indeed, the development of ATN during the course of HUS
is not particularly surprising, because one consequence of throm-
botic microangiopathy is tubular ischemia. Furthermore, hemo-
globinuria, a potential consequence of microangiopathic hemo-
lytic anemia, can directly cause ATN.
The central histopathologic features of BMT-associated HUS
are arteriolar and glomerular capillary injury with associated
thrombus formation (Fig. 4).Antignac and colleagues published a
detailed description of the microangiopathy [75]. In brief, the
arteriolar changes comprise marked luminal narrowing due to
mucoid intimal thickening, and fibrinoid material accumulation.
The underlying myocytes can be swollen or necrotic. The charac-
teristic glomerular lesion is "mesangiolysis" [86], a term denoting
dissolution of the mesangial cells and mesangial matrix with
accumulation of a spongiform material that can extend into
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glomerular capillary loops, producing a "double contour" appear-
ance of the peripheral capillary walls. Immunofluorescence mi-
croscopy characteristically demonstrates glomerular and arterio-
lar fibrin deposition. Coarse granular C3 deposits are frequently
observed in the muscular layer of arterioles. Electron microscopy
reveals edematous infiltration of the mesangium, matrix destruc-
tion, and accumulation of electron-lucent material within the
mesangial and sub-endothelial spaces with associated capillary
wall thickening and luminal encroachment. Endothelial cell swell-
ing, but not necrosis, is typically observed. Repeat biopsies
performed on a limited number of patients after the acute phase
of their disease have demonstrated that the disease can eventually
lead to increased mesangial matrix production, glomerular fibro-
sis, and chronic ischemic changes, characterized by wrinkling of
the glomerular basement membrane [75]. In addition, arteriolar
sclerosis can result. These changes provide a morphologic expla-
nation for persistent renal failure.
Although HUS can have diverse causes (for example, toxins,
infections, immunologic insults), increasing evidence strongly
suggests that in BMT patients, HUS is primarily a consequence of
cytoreductive therapy, particularly total-body irradiation (TB!).
The reasons for this assumption are as follows: (1) The his-
topathologic changes described, although not specific for radia-
tion nephritis, are completely consistent with this diagnosis [75,
87—90]. (2) Acute radiation nephritis typically has its onset 6 to 12
months after radiation, and this natural history is consistent with
the usual latency period seen in most cases of BMT-associated
HUS. (3) The presentation of radiation nephritis can be indistin-
guishable from that of classic HUS [75, 90]. (4) Although a
number of BMT-associated cases of HUS have presented within a
few weeks after cytoreductive therapy (as illustrated by the patient
described here), the literature clearly indicates that the expression
of radiation injury can be substantially shortened by concomitant,
or previous, chemotherapy (such as cyclophosphamide, bleomy-
cm, adriamycin, actinomycin D) or corticosteroid administration
[88, 89]. (5) Lawton and coworkers reported that partial renal
shielding during TB! reduced the incidence of post-BMT HUS
from 26% to 6% [85]; this finding strongly supports a cause-and-
effect relationship. (6) Total-body irradiation fractionation, which
is known to mitigate organ toxicity, appears to decrease the
incidence of post-BMT HUS [75; unpublished observations from
the Fred Hutchinson Cancer Center]. (7) The incidence of
BMT-associated HUS is approximately the same in CSA- versus
non-CSA-treated patients [801. Thus, although cyclosporine might
contribute to HUS in selected clinical circumstances [91], it does
not appear to be a prime cause of HUS in patients who have
undergone bone marrow transplantation.
The mechanism by which radiation injury causes HUS is not
completely understood. It is widely recognized, however, that
radiation's biologic effects are due to tissue energy deposition,
with differing susceptibilities being expressed by various cell types,
as well as by different intracellular constituents [921. Within the
kidney, endothelial cells appear to be the most susceptible. With
relatively low-dose exposure, single-stranded DNA breaks occur.
These can be repaired, but normal cells can lose their ability to
replicate; after 2 to 3 cell cycles, defective cells, or no cells, replace
the irradiated parent. The damage to the DNA and its ensuing
alterations probably explain the usual 4- to 12-month latency
period between total-body irradiation and the onset of HUS.
Presumably, the defective endothelium is predisposed to micro-
thrombus formation (for example, because of decreased prosta-
cyclin production [93]); this process culminates in HUS. If high-
dose radiation injury occurs, or if radiosensitizers are present,
such as radiomimetic chemotherapeutic drugs, double-stranded
DNA breaks and other critical cellular damage result, potentially
culminating in a more rapid expression of this syndrome. Fly-
droxyl radical (•OH), a byproduct of radiation's interaction with
cell water, is thought to be a prime mediator of radiation injury
[92]. Once formed, it triggers a cascade of oxidative reactions, the
results of which range from sublethal injury to cell death, depend-
ing on the target's susceptibility to oxidative damage. Tissue
resistance depends on the integrity of the cell's antioxidant
defense systems and whether superimposed stresses exist.
Regarding this latter possibility, we recently found that free
(non-protein-bound) iron frequently exists in the plasma of many
BMT patients. We obtained plasma samples from 38 patients 2 to
138 days following marrow infusion; we measured free ("catalyt-
ic") iron levels by the bleomycin assay technique [94]. This assay
is based on the principle that bleomycin addition to biologic
samples chelates the free iron that is present, and subsequently
the iron-bleomycin complex can be detected by its ability to
induce in-vitro oxidant DNA damage. Of the patients tested, 55%
had detectable free iron, with concentrations ranging from 0.1 to
5.0 tmol/liter. Because normal plasma contains no free iron
(because it is rapidly bound to transferrin), the finding of free iron
by this technique represented a distinctly unusual result. To
ascertain its cause and/or clinical relevance of the presence of the
iron, we conducted a retrospective chart review; the presence of
free iron strongly correlated with jaundice, particularly when it
was due to acute GVHD. Since the liver is an important iron
depot, we hypothesized that acute GVHD causes free-iron liber-
ation and that the iron circulates in a form capable of catalyzing
free-radical reactions. The clinical implications of the free-iron
liberation, and whether it increases the risk of HUS, remain
unknown. But the latter possibility seems plausible. Once within
the circulation, "catalytic" iron should have direct contact with
endothelial cells, and potentially can induce 'OH-driven oxidant
damage.
Given that TB! and oxidant stress are likely causes of BMT-
associated HUS, a number of strategies theoretically can be
employed to decrease radiation injury and hence the incidence of
HUS. These include partial renal shielding during TB! [851,
hyperfractionation of the radiation dose, slow radiation adminis-
tration (for example, from a cobalt source rather than from a
linear accelerator), and the provision of exogenous antioxidants/
'OH scavengers. But a potential problem exists with each of these:
decreased tumor cell killing might result, which is also free-radical
dependent. Provision of exogenous antioxidants also could impair
marrow engraftment and subsequent proliferation. For example, a
number of transcription factors are highly cell-redox-sensitive [95,
96]; therefore, provision of antioxidants ('OH scavengers, iron
chelators) theoretically could exert antiproliferative effects. Re-
cent experiments from this laboratory using a newly established
immortalized adult human kidney proximal tubular cell line, HK-2
[19], illustrate this point [97]. When subconfluent cultures of these
cells were incubated with a xanthine oxidase inhibitor (oxypuri-
nol) to decrease superoxide production, HK-2 outgrowth was
impaired. Proliferation also was inhibited when 'oH scavengers
(sodium benzoate or dimethylthiourea) were added. Conversely,
when the cells were challenged with sublethal oxidant stress
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(FeSO4-driven 0H production), proliferation was increased [97].
Although these results might have no direct relevance to therapy
given to prevent HUS, these data do indicate that antioxidants
could have unexpected and potentially undesirable effects in
marrow-transplant patients.
Once established, BMT-associated HUS is largely unresponsive
to all but supportive therapy. While plasma exchange, with or
without vincristine therapy, has been widely used because of its
reported efficacy in non-BMT-associated cases of HUS and
thrombotic thrombocytopenic purpura, its results have been dis-
appointing in BMT patients. For example, in one prospective
uncontrolled trial conducted on 8 patients, 4 were completely
unresponsive, while 4 showed some hematologic improvement
[83]. However, of these 8 patients, 7 died within one to 3 months
of disease onset. Thus, the therapeutic efficacy of plasma ex-
change remains unconvincing. Nevertheless, we usually employ a
trial of it (5 to 10 treatments) in the hope of achieving a clinical
response. Another unresolved issue is whether cyclosporine
should be withdrawn in these patients. Although it is unlikely that
CSA is responsible for hemolytic-uremic syndrome in the vast
majority of BMT-associated cases, its vasculotoxicity generally
prompts dose reduction or temporary discontinuation of the drug.
No proof exists that this is absolutely necessary and, if GVHD
appears to be life-threatening, CSA still might be indicated. Some
patients are left with end-stage renal failure, and hence require
maintenance dialysis. An interesting therapeutic possibility is
renal transplantation with a kidney from the marrow donor. Since
the donor marrow presumably has reconstituted the patient's
immune system, the kidney theoretically should be extremely well
tolerated. But no reports of this intriguing biologic experiment
have yet been reported.
Cyclosporine A nephrotoxicity. Both acute and chronic graft-
versus-host disease represent major complications of bone mar-
row transplantation, and moderate to severe GVHD is associated
with an approximate 10% to 50% mortality rate [98—100]. Since
its introduction in the early 1980s, cyclosporine has been a
mainstay of GVHD prophylaxis and treatment largely because,
unlike most immunosuppressive agents, it has no marrow inhibi-
tory effect. When used alone for prophylaxis against acute
GVHD, CSA has not been found superior to traditional metho-
trexate therapy. In combination with methotrexate or prednisone,
however, CSA decreases the incidence of acute GVHD; hence
cyclosporine is widely used within the first year following BMT
[99, 100]. At our institution, 3 mg/kg/day is given intravenously
initially in divided doses and subsequently 12.5 mg/kg/day is given
orally in divided doses as soon as the patient can tolerate it. After
50 days, the CSA is tapered by approximately 5% per week and,
in the absence of active GVHD, is discontinued at day 180.
Shortly after CSA's introduction for bone marrow transplanta-
tion, it became apparent that nephrotoxicity was a limiting
complication. For example, in one early trial comparing CSA to
conventional methotrexate prophylaxis in patients with acute
non-lymphoblastic leukemia, 33 of 36 CSA-treated patients expe-
rienced at least a doubling of their baseline serum creatinine
levels (to a mean peak value of 2.4 0.3 mg/dl), whereas only 18
of 39 methotrexate-treated patients did so (peak value of 1.2 0.1
mgldl) [100]. Similar results have been noted in several other
studies from our institution and others [101—104]. The risk of
acute CSA-induced renal dysfunction has generally correlated
reasonably well with serum/plasma CSA concentrations [105—
107]. For instance, in one study from London [107], the correla-
tions between trough CSA levels (as measured with a polyclonal
radioimmunoassay) and the BUN and creatinine concentrations
were 0.88 and 0.93 (r values) respectively. Concomitant nephro-
toxin use, most notably amphotericin B, appears to markedly
increase the risk of early CSA-associated renal dysfunction. In a
study from our institution, renal insufficiency, as defined by a
doubling of the serum creatinine, was noted in 19%, 38%, and
80% of patients treated with amphotericin plus methotrexate,
CSA alone, and amphotericin plus CSA, respectively [108].
Monitoring of trough CSA concentrations has been standard
practice in BMT patients because CSA levels clearly correlate
with the associated toxicities (for example, renal, hepatic, and
infectious complications; diastolic hypertension) as well as with
the risk of acute GVHD [98, 106]. But no consensus has been
reached as to which assay should be employed—high-perfor-
mance liquid chromatography (HPLC), radioimmunoassay, fluo-
rescence polarization immunoassay (FPIA); whether polyclonal
or monoclonal assays are preferable; or whether whole blood,
serum, or plasma should be used. Although it seems reasonable
that measurement of the parent compound (for example, by
HPLC, monoclonal immunoassay) would be superior to the use of
a polyclonal assay (which detects CSA and its metabolites), this
hypothesis has not been convincingly demonstrated. Indeed, one
group reported that trough serum CSA levels, as assessed by
polyclonal radioirnmunoassay, correlated better with the risk of
renal dysfunction than did parent CSA monitoring by HPLC [105,
109]. In 1986, our institution began monitoring plasma levels using
an FPIA (TDx; Abbott Laboratories, Chicago, Illinois); since that
time, CSA therapy has not had a statistically significant adverse
effect on early (1 month) post-transplant renal function.
Whether this reduction in acute CSA toxicity is due to the use of
this nonspecific assay (suggesting that CSA metabolites are in-
volved in the nephrotoxicity) or whether it reflects some other
undefined clinical variable remains unclear. However, it does
point out that parent drug monitoring currently is not mandatory
and, indeed, it might even be inferior to nonspecific assays for
predicting nephrotoxicity. Whole-blood assays have a theoretical
advantage over plasma/serum assays, as they can better gauge the
total-body CSA burden by providing an index of the drug's lipid
partitioning. No firm data exist to support this hypothesis in BMT
patients, however.
Given the frequency with which cyclosporine causes early
BMT-associated renal insufficiency, it is surprising that CSA has
not been implicated in the development of dialysis-requiring
ARF, at least at our institution. This lack of association has been
noted in three studies [32, 100, 101], and we recently confirmed
this finding in a prospective analysis of 355 patients undergoing
bone marrow transplantation in 1987 and 1988 (unpublished
data). Our most recent information suggests that neither CSA use,
daily dosage, total amount administered, nor plasma concentra-
tions predict the development of acute renal failure. A number of
potential explanations exist. First, CSA levels are routinely mon-
itored and dose adjustments are made for high levels. Second, if
unexplained azotemia develops, CSA doses are routinely reduced;
we thus presumably remove this contributing factor to ARF.
Third, since early BMT-associated ARF appears to be of hemo-
dynamic origin and is triggered by veno-occlusive disease, sepsis,
and amphotericin B, the vasoconstrictive effects of CSA may be
superfluous rather than additive in this situation. Nevertheless,
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when azotemia does develop in this patient population, CSA
should be temporarily reduced or discontinued, as there is no
other way to exclude its participation in causation of ARF in any
given individual.
Cyclosporine typically is given in full therapeutic doses for only
2 months in stable patients; not surprisingly, therefore, chronic
CSA nephrotoxicity has rarely been observed, For example, in a
comparison of our experience with patients treated with prophy-
lactic methotrexate versus methotrexate plus CSA, no significant
difference in serum creatinines was observed at one year post
BMT [104]. A group from Basel, Switzerland, reported that
patients tolerated very well 6 months of full CSA therapy,
followed by taper and withdrawal by one year [103]. These
observations have led to the assumption that patients who have
undergone bone marrow transplantation have a low risk of
chronic CSA-induced renal failure. But typical changes of chronic
CSA nephropathy (striped interstitial fibrosis, tubular atrophy,
arteriolopathy) have been documented in CSA-treated BMT
patients, particularly in those receiving prolonged therapy for
chronic GVHD [103, 110]. Since unrelated grafts are increasingly
being used for marrow transplantation, it is likely that more
chronic GVHD will result, leading to more prolonged CSA
therapy. Thus, more chronic CSA nephrotoxicity can be expected.
Conclusion
As the patient presented here demonstrates, bone marrow
transplantation is being applied more and more for therapy of a
broad variety of malignant and nonmalignant diseases. Its increas-
ingly frequent use will undoubtedly teach us more about its
therapeutic potential, the diseases for which it is used, and its
attendant complications. Bone marrow transplantation confers a
very high risk of acute renal failure, most notably due to a
hepatorenal-like syndrome and hemolytic-uremic syndrome.
Their occurrence, while life-threatening, offers nephrologists
unique opportunities to study the pathogenesis of these diseases
and their treatment in a prospective fashion. The effects of sepsis
on renal function also can be assessed, given an approximate 50%
incidence of sepsis within the first month following transplanta-
tion. Thus, in addition to its expanding therapeutic utility, bone
marrow transplantation offers unique research opportunities to
basic scientists and clinicians with highly varied investigative
interests.
Questions and answcrs
DR. NIcoLAos E. MADIAS, M.D. (Chief Division of Nephrology,
New England Medical Center, Boston, Massachusetts): It is surpris-
ing that there seems to be a low incidence of acute tubular
necrosis in the marrow transplant population, particularly during
the early transplant period, when sepsis and hypotension are so
frequent. Why do you think this might be so?
DR. ZAGER: That is an extremely interesting question. Unfor-
tunately, I can only speculate about the answer. As you point out,
marrow transplant patients have many risk factors for ATN,
particularly during the first 3 to 4 weeks following marrow
infusion, when most cytoreductive-therapy-associated complica-
tions develop. Some of these risk factors are directly related to
marrow aplasia, such as sepsis syndrome and, at times, thrombo-
cytopenia-related hemorrhagic shock. Severe liver disease is an-
other risk factor for ATN [111], and as I mentioned, hepatic
veno-occiusive disease is a frequent complication during this
period. Another potential risk factor is hyperthermia which, in the
experimental setting, profoundly worsens renal tubular injury
even in the absence of bacteremia [112, 113]. For example, if body
temperature is varied in rats from 32.0° to 39.5°C during renal
ischemia, the severity of post-ischemic tubular necrosis and
filtration failure directly and dramatically increase [112]. We have
documented this same injury-potentiating effect directly at the
cellular level with the use of isolated proximal tubular segments:
the higher temperature, the greater the amount of hypoxic tubular
injury [113]. This relationship partly can be explained by thermal
effects on cellular metabolic rates, since increasing the tempera-
ture decreases cellular ATP depletion during oxygen deprivation
[112, 113]. But because all cellular reactions are temperature
dependent, a change in energy profiles undoubtedly only partially
explains this phenomenon. Intermittent fevers are extremely
common within the first few weeks following marrow transplan-
tation; one therefore would presume that alterations in renal
susceptibility to injury would result.
Given these multiple risk factors, it is tempting for us to
postulate that the apparent infrequency of ATN is due to the
emergence of counterbalancing cytoprotective pathways that al-
low the kidney to withstand frequent and diverse tubular insults.
In fact, it has been recognized for at least 75 years that the kidney
can acquire cytoresistance to acute tubular injury [114]. For
example, following recovery from different types of nephrotoxic
acute renal failure, animals can withstand further toxic insults
[114]. Our laboratory has shown that renal tubular cytoresistance
also can emerge within 24 hours of ischemic renal injury [115].
Some of this cytoresistance can be attributed to reductions in
functional renal mass, as surgical renal ablation (1½ nephrec-
tomy) confers cytoresistance on the remaining nephrons [116,
117].
We are currently investigating the mechanisms underlying
acquired cytoresistance. To date, we know that it exists directly at
the cellular level, because proximal tubules extracted from rats
with ARF are protected against diverse forms of in-vitro injury
[117]. One attractive possibility is that cytoprotectant heat-shock
proteins (HSPs), synthesized by the kidney in response to diverse
forms of tissue injury, are responsible [117—120]. The fact that
hyperthermia is so common following marrow transplantation
could help explain why these patients are resistant to ATN. In my
view, however, it remains to be proven that HSPs actually protect
the kidney from acute tubular injury. For example, we have
induced hyperthermic heat shock in rats and produced marked
HSP synthesis (HSP-70); yet the severity of post-ischemic ARF
has not been affected (unpublished observations). Furthermore, if
proximal tubules are extracted from these "heat-shocked" kid-
neys, only trivial cytoresistance to in-vitro hypoxic injury is
observed [117]. These negative results have led us to explore
whether the increased expression of alternative cytoprotectant
molecules, such as antioxidant enzymes [30, 121, 1221 are respon-
sible, or whether functional/structural alterations induced within
tubular cells in the aftermath of injury account for the cytopro-
tection.
DR. MADIAs: What is the natural history of the veno-occlusive-
disease-induced hepatorenal syndrome? Second, is there an ani-
mal model that has been used to study it?
DR. ZAGER: The outcome of veno-occlusive-disease (VOD)-
associated renal failure largely depends on the severity of the
underlying hepatic disease. If the hepatic disease is relatively
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modest, patients generally recover from it and from the frequently
accompanying renal insufficiency. Severe VOD, which is graded
according to a number of clinical and laboratory parameters [42],
confers an ominous prognosis. For example, McDonald et al
prospectively analyzed the incidence of VOD in 355 patients
undergoing BMT [42]. The incidence of mild, moderate, and
severe VOD in these patients was 12%, 26%, and 15% respec-
tively, whereas the incidence of ARF for these groups was 10%,
10%, and 54%, respectively. Of the 54 patients who had severe
VOD, 53 died, most with ARF. Overall, ARF requiring dialysis is
associated with an approximate 85% risk of death [32]. In many
ways, the natural history of VOD-associated renal failure mimics
that of the hepatorenal syndrome: if the patient has reversible
liver failure, recovery from ARF also occurs. However, if the
hepatic disease is unremitting, death in ARF can be expected.
Regarding the second part of your question, a few animal
models of hepatic VOD have been established; these involve
giving hepatic irradiation and chemotherapy [123, 124]. These
models have not produced ARF, however. Perhaps this indicates
that VOD alone is insufficient to produce ARF, and that addi-
tional precipitating factors, such as sepsis syndrome and ampho-
tericin B, are important. This is certainly our clinical experience,
as most patients with VOD develop acute renal failure only after
the onset of sepsis.
DR. JOHN T. HARRINGTON (Chief of Medicine, Newton- Wellesley
Hospital, Newton, Massachusetts): Is there a way of blocking the
cytokines thought to be involved in the pathogenesis of marrow-
transplant-associated VOD? If so, have cytokine-blocking agents
been administered clinically to see whether they protect the
kidney?
DR. ZAGER: The cytokine most implicated in the pathogenesis
of VOD, and in other forms of chemoradiotherapy toxicities, is
TNFa. Early post-transplant plasma levels of TNFa correlate with
the development of VOD as well as with GVHD and noninfec-
tious pneumonitis [125]. Synthesized both by activated phagocytes
and nonphagocytic cells, TNFa has diverse biologic actions. In
regard to VOD, it is thought to exert a procoagulant effect,
stimulate the production of inflammatory prostanoids, and cause
the generation of superoxide radicals. Together these processes
can lead to hepatic venular damage, thrombosis, and reticulum
and collagen deposition [37]. Pentoxifylline is a synthetic xanthine
derivative that downregulates TNFa production [58]. It had been
suggested that its use can decrease the severity of both sepsis
syndrome and radiation-induced lung injury [126]. These consid-
erations led to clinical trials in marrow transplant patients. In a
phase I-I! trial, 30 patients were treated with PTX from the start
of conditioning therapy through hospital discharge, and hepatic
disease and renal insufficiency decreased [581. Unfortunately, a
more recent randomized trial showed no benefit [59].
DR. AJAY SINGFI (Division of Nephrology, New England Medical
Center): Is there any evidence for endothelial cell damage outside
the liver in VOD?
DR. ZAGER: Chemoradiotherapy likely induces widespread
endothelial damage, but to my knowledge, the only other organ
that develops venous occlusions is the lung. In one autopsy study,
the incidence of pulmonary endothelial swelling and localized
venous thromboses was approximately 50% [127]. Yet clinically
significant pulmonary VOD is thought to be quite uncommon,
although it has been reported [128, 129]. Why the liver appears to
be uniquely susceptible to this complication of cytoreductive
therapy is unknown.
DR. SINGH: Has anyone measured endothelin levels in these
patients?
DR. ZAGER: Not to my knowledge. We are just starting a
prospective analysis of circulating endothelin and nitric oxide
levels to assess whether they predict, or correlate with, the
development of VOD and renal failure. Our working hypothesis is
that chemoradiotherapy induces endothelial damage, which leads
to increased endothelin or decreased nitric oxide production, and
which culminates in renal vasoconstriction and a hemodynamic
form of ARF. That patients with hepatorenal syndrome have
increased circulating levels of endothelin [48] offers support for
this possibility.
DR. SINGH: Has TNF been injected into normal animals? To my
knowledge, it doesn't cause any damage and therefore might only
predispose the kidney to other forms of injury.
DR. ZAGER: I believe that you are correct. We have addressed
this issue experimentally by injecting either purified endotoxin or
E. coli into rats; both substances cause TNF release. Although
renal blood flow decreased, we noted no tubular necrosis or
sustained reduction in GFR. If we induced endotoxemia at the
time of one-shot gentamicin administration, however, severe ARF
and focal ATN resulted [130]. Although the endotoxemia in-
creased proximal tubular gentamicin uptake, this change alone
could not explain the induction of renal failure. Endotoxemia and
TNF also increase the severity of postischemic and myohemoglo-
binuric ARF [131, 132] and likely potentiate diverse forms of
proximal renal tubular cell injury. Alternatively, induction of
endotoxin tolerance can protect against subsequent renal injury
[130, 131].
DR. RONALD PERRONE (Division of Nephrology, New England
Medical Center): The few marrow transplant patients I've seen are
beyond the marrow aplasia phase and have been on 5 to 10
different drugs, some of which are potentially nephrotoxic. It's
always hard to pin down exactly what's causing azotemia in these
patients. Do you have any thoughts regarding these patients?
DR. ZAGER: I'm sympathetic to that plight. It can be extremely
difficult to identify the underlying cause. If the onset of the renal
insufficiency can be identified by reviewing the serum creatinine
concentrations, the medication history immediately preceding
that date might be helpful in implicating a specific agent. The
onset of renal insufficiency during this time raises the possibility of
the hemolytic-uremic syndrome. We would look carefully at the
urinalysis for proteinuria, new-onset hematuria or RBC casts, and
hematologic markers of HUS, such as schistocytes, a falling
hematocrit, a rise in LDH, or a decrease in the platelet count. If
none of these approaches suggested a cause for the renal insuffi-
ciency, we would try to exclude cyclosporine toxicity by tempo-
rarily reducing the dose, particularly if the blood levels were not
low and there were no active GVHD.
DR. MADIAs: As I recall, some people have speculated as to
whether the incidence of membranous nephropathy increases in
the aftermath of bone marrow transplantation, possibly related to
the development of GVHD. What information is available regard-
ing this issue?
DR. ZAGER: Since 1988, 5 patients with chronic GVHD have
been described who have heavy proteinuria and in whom renal
biopsies have shown light and/or electron microscopic changes
suggestive of membranous nephropathy [133—136]. Given that a
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murine model of chronic GVHD is associated with immunologic
glomerular disease [137], these cases might have been GVHD
induced. That 3 of these patients experienced reductions in
proteinuria with immunosuppressive treatment of their GVHD
also suggests a pathogenetic link [133, 135]. Despite this evidence
suggesting a causal relationship, a number of potential caveats
need to be considered. First, 2 of the reported patients did not
demonstrate immunoglobulin deposition in glomerular basement
membranes; therefore, the nature of the electron-dense basement
membrane deposits remains unresolved [135]. Second, 2 of the
patients had prominent mesangial proliferation [135], which is
inconsistent with typical membranous nephropathy. Third, non-
specific glomerular changes, including mesangial proliferation and
sclerosis, thickening and splitting of basement membranes, and
GBM deposits have been observed following BMT in the absence
of clinical renal disease, possibly as delayed consequences of
cytoreductive therapy [138]. Fourth, a remission of glomerulopa-
thy during immunosuppression of GVHD does not necessarily
link the two diseases; idiopathic membranous nephropathy fre-
quently responds to immunosuppressive therapy. Therefore, I
think it is unclear whether a causal or a chance association
between GVHD and membranous nephropathy exists.
DR. ANrnuw KJNG (Division of Nephrology, New England Med-
ical Center): Let me return to Dr. Singh's earlier question.
Endothelial damage and renal vasoconstriction raise the question
of a disproportionate increase in endothelium-derived vasocon-
strictors, compared to vasodilators. One of the characteristics of
radiation nephritis is severe hypertension. Could you comment on
whether endothelium-derived vasoactive compounds play a role?
DR. ZAGER: The form of endothelium-derived vasoconstrictors
and vasodilators in radiation-nephritis-induced hypertension has
not been defined. We see a significant amount of mild hyperten-
sion in marrow transplant patients, but it usually is due to either
cyclosporine or corticosteroid therapy. Accelerated or malignant
hypertension, characteristic of radiation nephritis, is quite unusual
in marrow transplant patients, except if severe HUS is present,
probably because patients undergoing marrow transplantation
generally receive only 8—14 Gy of radiation. In contrast, typical
radiation nephritis requires approximately 23—25 Gy to develop.
The use of cytotoxic drugs such as cyclophosphamide as part of
cytoreductive therapy reduces the amount of irradiation needed
and probably prevents the development of classic radiation ne-
phritis and its attendant hypertensive complications.
DR. RIcunD LAFAYETFE (Division of Nephroloy, New England
Medical Center): You excluded acute tubular necrosis as the
diagnosis in these patients who have many risk factors. It is well
known that patients can have ATh with a low urinary sodium
concentration if they have either nonoliguric ATh or an ineffec-
tive circulating blood volume. What else have you done to exclude
the possibility of tubular necrosis in the marrow-transplant pa-
tients?
DR. ZAGER: We too have been impressed that many patients
with nonoliguric ATN have low urinary sodium concentrations.
Therefore, renal sodium retention alone does not exclude ATN in
patients with VOD-associated acute renal failure. In BMT pa-
tients, however, sodium avidity always precedes the onset of
azotemia by many days. Thus it is the first evidence of the renal
failure rather than a secondary manifestation of it. The observa-
tion by Bearman et al that partial resolution of hepatic VOD with
t-PA and heparin therapy improves renal function [56] also
suggests a hemodynamic form of ARF. If the renal failure were
due to ATN, a reduction in portal hypertension would not
immediately improve renal function. We also have reviewed
autopsy material from 36 patients who died with ARF to look for
histologic evidence of ATN. Although post-mortem autolysis
makes it difficult to definitively exclude ATN, we found only one
patient who had morphologic evidence of tubular necrosis [32].
DR. MArus: Although you separated temporally the veno-
occlusive renal failure syndrome from HUS, my own experience
suggests that these two entities might co-exist. Indeed, the same
factors that induce endothelial damage in hepatic venules also
might damage the endothelium of arterioles.
DR. ZAGER: I agree, and the patient presented today illustrates
your point. Veno-occlusive disease is generally seen one to 3
weeks after transplantation, and HUS most often occurs 4 to 12
months later, but the two entities can co-exist. As I said earlier,
previous exposure to chemoradiotherapy can accelerate the onset
of post-transplant HUS, potentially allowing it to overlap with the
VOD syndrome.
DR. HARRINGTON: I believe you said that patients whose serum
creatinine levels fell in response to volume loading were not likely
to develop acute renal failure compared with patients whose
serum creatinine levels did not fall. Could you quantitate your
comment?
DR. ZAGER: In our retrospective analysis of 272 patients who
underwent marrow transplantation, the mean serum creatinines
just prior to marrow infusion for patients who subsequently did or
did not develop ARF were 0.75 and 0.65 mg/dl respectively [32].
This was a highly significant, but quantitatively trivial, difference.
It was interesting that both groups of patients had relatively low
serum creatinine levels, compared with the normal range of
0.6—1.4 mg/dl. We ascribe these low values to the fact that these
patients undergo vigorous volume expansion as part of their
conditioning regimen, possibly calling into play their renal func-
tional reserve. If this assumption is true, the possibility exists that
seemingly trivial decrements in baseline renal function, or in the
amount of renal functional reserve, might confer on these patients
an increased risk of developing VOD-associated acute renal
failure. But this remains a hypothesis that has not been directly
tested in a prospective fashion.
DR. SvnmomR N. NATOV (Clinical Research Fellow in Nephrol-
ogy, New England Medical Center): I have a question regarding
viral infections in bone marrow transplantation. Herpes viruses,
particularly CMV, can be transmitted with the allograft, and CMV
is a major cause of morbidity and mortality in allogeneic bone
marrow recipients [139]. Transmission with the transplant also has
been shown for hepatitis B and hepatitis C viruses. Would you
please comment on the impact of these viral infections on liver
failure, and whether some of these viruses can cause any specific
type of renal injury, as this has been reported for CMV in renal
transplantation [140].
DR. ZAGER: Viral hepatitis, particularly due to hepatitis C,
affects approximately 20% of bone-marrow-transplant candidates
[37]. Most of the attendant risks for post-transplant hepatitis
come from these pre-existing infections, rather than from new
viral transmission during the transplant or post-transplant period.
The existence of pre-transplant hepatitis does impose significant
risks [37]: (1) it is a major risk factor for hepatic VOD; (2) a
fulminant flair of the hepatitis can result in the post-transplant
period; and (3) chronic progressive liver disease can ensue. I know
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of no specific post-marrow-transplant renal syndromes with a
direct viral cause. Because viral hepatitis is a major risk factor for
VOD, however, it undoubtedly threatens post-transplant renal
function, even if only indirectly.
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